Breaking Medical
Technology Stock News: Aethlon Medical (NASDAQ: $AEMD) Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier®
in Removing Extracellular Vesicles From Cancer Patient Plasma
SAN DIEGO, CA, May
10, 2024 - (Investorideas.com Newswire) Aethlon Medical, Inc. (NASDAQ:AEMD), a medical
therapeutic company focused on developing products to treat cancer and
life-threatening infectious diseases, today announced positive results from an in
vitro binding study of its Hemopurifier® in removing extracellular vesicles (EVs)
from plasma. The translational study provides pre-clinical evidence to support Aethlon’s planned phase 1 safety, feasibility and
dose-finding clinical trials of the Hemopurifier in patients with solid tumors
who have stable or progressive disease during anti-PD-1 monotherapy treatment,
such as Keytruda® or Opdivo®.
This news is paid advertisement/ news disseminated
on behalf of/issued on behalf of Aethlon Medical Inc.
Read this news,
featuring AEMD in full at https://www.investorideas.com/news/2024/05101AEMD-Hemopurifier-in-Removing-Extracellular-Vesicles.asp
"The
positive data from this in vitro binding study of the Hemopurifier is an
important step forward for Aethlon, ahead of the potential start of our planned
phase 1 oncology trials in Australia and India,” stated James Frakes, Interim
Chief Executive Officer and Chief Financial Officer of Aethlon Medical. “We have
previously demonstrated that our Hemopurifier can reduce EVs isolated from
cancer patient plasma when those EVs are placed in a buffer solution. However, ahead
of our oncology study, we wanted to conduct a more robust translational study,
specifically examining the removal of EVs and EVs with PD-L1 on their surface
directly from plasma. To that end, we acquired small volumes of plasma from
patients treated with anti-PD-1 antibodies from a third-party lab and ran the
samples over a miniature version of our Hemopurifier. We then had the samples examined
by Cellarcus Biosciences, Inc., an independent commercial lab with recognized
expertise in EV quantification and phenotyping, by the widely accepted
methodology of vesicle flow cytometry. This data was then analyzed by independent
statisticians at NAMSA, the contract research organization (CRO) for our
planned Australian oncology study.”
Mr. Frakes
concluded, “The descriptive statistics from the CRO support the removal of EVs
by the Hemopurifier directly from cancer patient plasma, although the small
numbers of EVs bearing PD-L1 did not allow us to conclude a removal of this
particular EV subset. We look forward to adding this data to our Clinical
Investigator Brochure and submitting it to the Ethics Committees at the
interested clinical sites, as the next step for our planned phase 1 oncology
trials in Australia and India.”
About Aethlon and the Hemopurifier®
Aethlon Medical
is a medical therapeutic company focused on developing the Hemopurifier, a
clinical stage immunotherapeutic device which is designed to combat cancer and
life-threatening viral infections and for use in organ transplantation. In
human studies, the Hemopurifier has demonstrated the removal of life-threatening
viruses and in pre-clinical studies, the Hemopurifier has demonstrated the
removal of harmful exosomes from biological fluids, utilizing its proprietary
lectin-based technology. This action has potential applications in cancer,
where exosomes may promote immune suppression and metastasis, and in
life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug
Administration (FDA) designated Breakthrough Device indicated for the treatment
of individuals with advanced or metastatic cancer who are either unresponsive
to or intolerant of standard of care therapy, and with cancer types in which
exosomes have been shown to participate in the development or severity of the
disease. The Hemopurifier also holds an FDA Breakthrough Device designation and
an open Investigational Device Exemption (IDE) application related to the
treatment of life-threatening viruses that are not addressed with approved
therapies.
Additional
information can be found at www.AethlonMedical.com.
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties.
Statements containing words such as "may," "believe,"
"anticipate," "expect," "intend,"
"plan," "project," "will,"
"projections," "estimate," "potentially" or
similar expressions constitute forward-looking statements. Such forward-looking
statements are subject to significant risks and uncertainties and actual
results may differ materially from the results anticipated in the
forward-looking statements. These forward-looking statements are based upon
Aethlon's current expectations and involve assumptions that may never
materialize or may prove to be incorrect. Factors that may contribute to such
differences include, without limitation, the Company's ability to successfully
complete development of the Hemopurifier and to successfully demonstrate the
utility of the Hemopurifier in patients
with solid tumors in our planned oncology clinical trials, , the Company’s
ability to obtain the approval by the respective Ethics Boards of interested
clinical trial sites in India and in Australia; the Company’s ability to manage its clinical trials,
and other potential risks. The foregoing list of risks and uncertainties is
illustrative but is not exhaustive. Additional factors that could cause results
to differ materially from those anticipated in forward-looking statements can
be found under the caption "Risk Factors" in the Company's Annual
Report on Form 10-K for the year ended March 31, 2023, and in the Company's other
filings with the Securities and Exchange Commission, including its quarterly
Reports on Form 10-Q. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Except as may be
required by law, the Company does not intend, nor does it undertake any duty,
to update this information to reflect future events or circumstances.
Company Contact:
Jim Frakes
Interim Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
917-513-5303
Aethlon Medical Inc. (Nasdaq:AEMD) is a featured
biotech stock on Investorideas.com
More info on AEMD at
Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/
Get News Alerts on Aethlon Medical
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced
news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investing involves risk and possible
losses. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. Contact management and IR of
each company directly regarding specific questions. Disclosure: Aethlon
Medical, Inc. (NASDAQ:AEMD) is a paid featured stock on Investorideas.com More
disclaimer info: https://www.investorideas.com/About/News/Clientspecifics.asp
https://www.investorideas.com/About/Disclaimer.asp
Learn more about
publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of
each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Biotech
Industry Stocks- investing ideas in biotechnology stocks, medical technology
and life sciences
Like Biotech
Stocks? View our Biotech
Stocks Directory
Get News Alerts on Biotech Stocks
No comments:
Post a Comment